|
|
Article: Nabi acquires exclusive rights to Phase III organ transplantation rejection antibody product.
- Article from:
- BIOTECH Patent News
- Article date:
- March 1, 2006
CopyrightCOPYRIGHT 2006 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Nabi Biopharmaceuticals (Boca Raton, FL) has signed an agreement with Fresenius Biotech to advance the development of ATG-Fresenius S in the United States and Canada. ATG-Fresenius S is an immunosuppressive polyclonal antibody product used for the prevention and treatment of acute rejection following organ transplantation. The product, which Fresenius currently markets in more than 60 countries worldwide, has been shown to significantly reduce transplant failure and substantially improve survival rates.
Under the terms of the agreement, Fresenius Biotech has granted Nabi Biopharmaceuticals exclusive sales and distribution rights to ATG-Fresenius S in the United ...